Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05050799 · ClinicalTrials.gov registry record
US Post-Market Surveillance Study of the Surfacer System
A clinical trial of Venous Disease, sponsored by Merit Medical Systems.
- Recruiting
- Registry status
- 30
- Enrollment target
- 6
- Study locations
NCT05050799: Recruiting study of Venous Disease, sponsored by Merit Medical Systems.
NCT05050799 is a study of Venous Disease that is actively recruiting participants, run by Merit Medical Systems. The registered enrollment target is 30 participants, below the 206-participant average among 6 other Venous Disease trials with a reported enrollment target (85% lower). The trial reports 6 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05050799, a study of Venous Disease, is actively recruiting participants, sponsored by Merit Medical Systems.
- RECRUITING
- Registry status
- 30 participants
- Enrollment target
- 6
- Study locations
Study Summary
Single arm, observational, multi-center, consecutively enrolling, post-market surveillance study. Treating patients in need of central venous access who have upper body venous occlusions or other conditions that preclude central venous access by conventional methods, and who meet the requirements described in the device labeling.
Primary Outcome
safe insertion of the device to facilitate central venous access
Conditions Studied
Interventions
- DEVICE Central Venous Access
Study Locations (6)
Texas
- Baylor Scott & White Heart and Vascular Hospital - Dallas
- The University of Texas Health Science Center at Houston - Houston
- Flow Vascular Institute - Pasadena
Arizona
- Pima Heart and Vascular - Tucson
Florida
- Sarasota Memorial Health Care System - Sarasota
Utah
- St. Mark's Hospital - Millcreek
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-02-08 |
| Est. Completion | 2026-12-15 |
What NCT05050799 shows while recruiting
NCT05050799 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 206-participant average among 6 other Venous Disease trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Venous Disease appearing as the primary indexed condition, and to 1 intervention - of which Central Venous Access is the first listed.
NCT05050799 lists 6 locations in 4 states (Texas, Arizona, Florida).
Frequently Asked Questions
What is clinical trial NCT05050799 about?
NCT05050799 is a clinical study titled "US Post-Market Surveillance Study of the Surfacer System". Single arm, observational, multi-center, consecutively enrolling, post-market surveillance study. Treating patients in need of central venous access who have upper body venous occlusions or other conditions that preclude central venous access by conventional methods, and who meet the requirements de...
What is the current status of trial NCT05050799?
This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2022-02-08. Estimated completion is 2026-12-15.
What conditions does trial NCT05050799 study?
This clinical trial studies the following conditions: Venous Disease.
What interventions are being tested in trial NCT05050799?
The interventions under investigation include: Central Venous Access (DEVICE).
Who is sponsoring clinical trial NCT05050799?
This trial is sponsored by Merit Medical Systems, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05050799 being conducted?
This trial has 6 study locations across Arizona, Florida, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Venous Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The GORE® VIABAHN® FORTEGRA Venous Stent Iliofemoral Study
RECRUITING · NA
-
Vascular Lab Resource (VLR) Biorepository
RECRUITING
-
The GORE® VIABAHN® FORTEGRA Venous Stent IVC Study
ACTIVE NOT RECRUITING · NA
-
BARD® The VENOVO™ Venous Stent Study for Treatment of Iliofemoral Occlusive Disease
COMPLETED · NA
-
Cooling Lower Leg Skin to Prevent Venous Leg Ulcers in Patients With Poor Vein Circulation
COMPLETED · Phase 1
-
Prevalence of MTHFR Polymorphisms in Venous Disease
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI